Eli Lilly raises outlook as Zepbound and Mounjaro sales surge past estimates

Eli Lilly easily beat quarterly earnings estimates and raised its 2026 revenue guidance to between $85 billion and $87 billion, up from the previous range of $82–$85 billion. The surge was driven by soaring sales of its obesity drugs Zepbound and Mounjaro. The results reinforce the company's dominance in the GLP-1 drug market.